

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

 (43) International Publication Date: 12 October 2000 (12.10.00 (21) International Application Number: PCT/US00/08821 (22) International Filing Date: 31 March 2000 (31.03.00) (30) Priority Data: 60/127,595 2 April 1999 (02.04.99) (31) March 2000 (20.04.99) (32) Applicant (for all designated States except US): KINETIC (43) International Publication Date: 12 October 2000 (12.10.00 (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KC, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MI MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SS, TZ, UG, ZW), Eurasian patent (AT, BE, CH, CY, DD, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE 	51) International Patent Classification 7 :	1	(11) International Publication Number: WO 00/59424
 32) International Filing Date: 31 March 2000 (31.03.00) 33) Priority Data: 60/127,595 2 April 1999 (02.04.99) US 34) Priority Data: 60/127,595 2 April 1999 (02.04.99) US 35) Priority Data: 60/127,595 2 April 1999 (02.04.99) US 36) Priority Data: 60/127,595 2 April 1999 (02.04.99) US 37) Applicant (for all designated States except US): KINETIC CONCEPTS, INC. [US/US]; 8023 Vantage Drive, San Antonio, TX 78203 (US). 37) Inventor: and (75) Inventor: Applicant (for US only): JOHNSON, Royce, W. [US/US]; 114 Rimdale, Universal City, TX 78148 (US). 38) File: VACUUM ASSISTED CLOSURE SYSTEM WITH PROVISION FOR INTRODUCTION OF AGENT 39) Title: VACUUM ASSISTED CLOSURE SYSTEM WITH PROVISION FOR INTRODUCTION OF AGENT 	A61F 13/00, A61M 1/00	A1	(43) International Publication Date: 12 October 2000 (12.10.00
	 22) International Filing Date: 31 March 2000 (30) Priority Data: 60/127,595 2 April 1999 (02.04.99) 71) Applicant (for all designated States except US): CONCEPTS, INC. [US/US]; 8023 Vantage D Antonio, TX 78230 (US). 72) Inventor; and 75) Inventor/Applicant (for US only): JOHNSON, R [US/US]; 114 Rimdale, Universal City, TX 78148 (74) Agents: COLTON, Wayne, J.; Wayne J, Colton, Milam Building, Suite 1108, 115 East Travis S 	(31.03.0 KINET rrive, S Coyce, ' 8 (US). Inc., T	 BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GI GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KC KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MH MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YI ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SI SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KMD, RU, TJ, TM), European patent (AT, BE, CH, CY, DI DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, MI MR, NE, SN, TD, TG). V. Published With international search report.
12			

A method, and apparatus for the introduction to a wound under vacuum assisted closure (VAC) therapy of a wound healing agent, generally comprises a foam pad (11) for insertion substantially into a wound site (12), and a wound drape (13) for sealing enclosure of the foam pad at the wound site. The foam pad is placed in fluid communication with a vacuum source for promotion of fluid drainage. Additionally, the foam pad is predisposed, through grafting or other techniques known to those of ordinary skill in the art, with basic fibroblast growth factor (bFGF), anti-microbial or other factors, also known to those of ordinary skill in the art, for the promotion of increased wound healing.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

	2	-	•				
AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	ТМ	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
СМ	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	РТ	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

VACUUM ASSISTED CLOSURE SYSTEM WITH PROVISION FOR INTRODUCTION OF AGENT

RELATED APPLICATION:

5

This application claims priority to United States provisional patent application Serial No. 60/127,595 entitled VACUUM ASSISTED CLOSURE SYSTEM WITH PROVISION FOR INTRODUCTION OF AGENT filed April 2, 1999. By this reference, the full disclosure, including the drawings, of U.S. provisional patent application Serial No. 60/127,595 is incorporated herein.

10

TECHNICAL FIELD:

The present invention relates to the healing of wounds. More specifically, the present invention relates to the vacuum assisted closure (VAC) of wounds wherein a growth factor or other agent is introduced to a wound site through grafting with a VAC pad in order to facilitate wound healing.

15

BACKGROUND ART:

Wound closure involves the inward migration of epithelial and subcutaneous tissue adjacent the wound. This migration is ordinarily assisted through the inflammatory process, whereby blood flow is increased and various functional cell types are activated. Through the 20 inflammatory process, blood flow through damaged or broken vessels is stopped by capillary level occlusion, whereafter cleanup and rebuilding operations may begin. Unfortunately, this process is hampered when a wound is large or has become infected. In such wounds, a zone of stasis (i.e. an area in which localized swelling of tissue restricts the flow of blood to the 25 tissues) forms near the surface of the wound.

Without sufficient blood flow, the epithelial and subcutaneous tissues surrounding the wound not only receive diminished oxygen and nutrients, but are also less able to successfully fight bacterial infection and thus are less able to naturally close the wound. Until recently, such difficult wounds were addressed only through the use of sutures or staples.

Although still widely practiced and often effective, such mechanical closure techniques 30 suffer a major disadvantage in that they produce tension on the skin tissue adjacent the wound. In particular, the tensile force required in order to achieve closure using sutures or staples causes very high localized stresses at the suture or staple insertion point. These stresses commonly result in the rupture of the tissue at the insertion points, which can

PCT/US00/08821

eventually cause wound dehiscence and additional tissue loss.

Additionally, some wounds harden and inflame to such a degree due to infection that closure by stapling or suturing is not feasible. Wounds not reparable by suturing or stapling generally require prolonged hospitalization, with its attendant high cost, and major surgical procedures, such as grafts of surrounding tissues. Examples of wounds not readily treatable with staples or suturing include large, deep, open wounds; decubitus ulcers; ulcers resulting from chronic osteomyelitis; and partial thickness burns that subsequently develop into full thickness burns.

- As a result of these and other shortcomings of mechanical closure devices, methods and apparatus for draining wounds by applying continuous negative pressures have been developed. When applied over a sufficient area of the wound, such negative pressures have been found to promote the migration toward the wound of epithelial and subcutaneous tissues. In practice, the application to a wound of negative pressure, commonly referred to as vacuum assisted closure (VAC) therapy, typically involves mechanical-like contraction of the wound with simultaneous removal of excess fluid. In this manner, VAC therapy augments the body's natural inflammatory process while alleviating many of the known intrinsic side effects, such as the production of edema caused by increased blood flow absent the necessary vascular structure for proper venous return.
- While VAC therapy has been highly successful in the promotion of wound closure, healing many wounds previously thought largely untreatable, some difficulty remains. Because the inflammatory process is very unique to the individual patient, even the addition of VAC therapy does not result in a fast enough response, especially during the occlusion and initial cleanup and rebuilding stages, for adequate healing of some wounds. It is therefore a principle object of the present invention to provide a method and apparatus whereby the known VAC therapy modalities are improved through the introduction of growth factors and/or other agents that facilitate wound healing.

DISCLOSURE OF THE INVENTION:

In accordance with the foregoing objects, the present invention – a method and apparatus for the introduction to a wound undergoing vacuum assisted closure (VAC) therapy of a wound healing agent – generally comprises a foam pad for insertion substantially into a wound site and a wound drape for sealing enclosure of the foam pad at the wound site. According to the invention, the foam pad is placed in fluid communication with a vacuum source for promotion of fluid drainage. Additionally, the foam pad is predisposed, through

PCT/US00/08821

grafting or other techniques known to those of ordinary skill in the art, with basic fibroblast growth factor (bFGF), anti-microbials or other factors, also known to those of ordinary skill in the art, for the promotion of increased wound healing.

According to the preferred method of the present invention, a growth factor or other wound healing agent is added to the previously known VAC therapy through modification as necessary of the VAC system's foam pad. Such growth factors as the basic fibroblast growth factor (bFGF) are known to accelerate wound healing due to their potent angiogenesis and granulation tissue formation activities. As has been demonstrated even with difficult to heal wounds, such as infected wounds, burn wounds and diabetic wounds, the resultant activities lead to the rapid reepitherialization and contraction of the wound. The combination of VAC therapy with growth factor introduction, through the modification of the foam pad and predisposition thereof with the bFGF, is therefore thought to be an important contribution to

Finally, many other features, objects and advantages of the present invention will be apparent to those of ordinary skill in the relevant arts, especially in light of the foregoing discussions, the following drawing and exemplary detailed description and the claims

BRIEF DESCRIPTION OF THE DRAWINGS:

the wound healing arts.

appended hereto.

20

Although the scope of the present invention is much broader than any particular embodiment, a detailed description of the preferred embodiment follows together with an illustrative figure, wherein like reference numerals refer to like components, and wherein:

The figure shows, in partially cut away perspective view, the preferred embodiment of the present invention as applied to a mammalian wound site.

25

30

BEST MODE FOR CARRYING OUT THE INVENTION:

Although those of ordinary skill in the art will readily recognize many alternative embodiments, especially in light of the illustrations provided herein, this detailed description is exemplary of the preferred embodiment of the present invention - a vacuum assisted closure system with provision for introduction of agent, the scope of which is limited only by the claims appended hereto.

Referring now to the figure, the present invention 10 is shown to generally comprise a foam pad 11 for insertion substantially into a wound site 12 and a wound drape 13 for sealing enclosure of the foam pad 11 at the wound site 12. According to the invention, the 10

PCT/US00/08821

foam pad 11 is placed in fluid communication with a vacuum source for promotion of fluid drainage. Additionally, the foam pad 11 is predisposed, through grafting or other techniques known to those of ordinary skill in the art, with basic fibroblast growth factor (bFGF), antimicrobials or other factors, also known to those of ordinary skill in the art, for the promotion

5 of increased wound healing.

According to the preferred embodiment of the present invention, the foam pad 11, wound drape 13 and vacuum source are implemented as known in the prior art, each of which is detailed in U.S. patent application Serial No. 08/517,901 filed August 22, 1995. By this reference, the full disclosure of U.S. patent application Serial No. 08/517,901 ("the '901 application"), including the claims and the drawings, is incorporated herein as though now set forth in its entirety. Additionally, such a VAC system is readily commercially available through Kinetic Concepts, Inc. of San Antonio, Texas, U.S.A. and/or its subsidiary companies.

As detailed in the '901 application, the foam pad 11 preferably comprises a highly reticulated, open-cell polyurethane or polyether foam for good permeability of wound fluids while under suction, but in this application may comprise a conventional sponge cellulose type dressing as necessary for introduction of the desired agent. As also detailed in the '901 application, the foam pad 11 is preferably placed in fluid communication, via a plastic or like material hose 14, with a vacuum source, which preferably comprises a canister safely placed under vacuum through fluid communication, via an interposed hydrophobic membrane filter, with a vacuum pump. Finally, the '901 application also details the wound drape 13, which preferably comprises an elastomeric material at least peripherally covered with a pressure sensitive, acrylic adhesive for sealing application over the wound site 12.

According to the preferred method of the present invention, those components as are described in the '901 application are generally employed as known in the art with the exception that the foam pad 11 of the present invention is modified as necessary for the introduction of a growth factor. Such growth factors as the basic fibroblast growth factor (bFGF) are known to accelerate wound healing due to their potent angiogenesis and granulation tissue formation activities. As has been demonstrated even with difficult to heal wounds, such as infected wounds, burn wounds and diabetic wounds, the resultant activities lead to the rapid reepitherialization and contraction of the wound. The combination of VAC therapy with growth factor introduction, through the modification of the foam pad 11 and predisposition thereof with the bFGF, is therefore thought to be an important contribution to the wound healing arts. Likewise, the present method presents an excellent opportunity for

WO 00/59424

PCT/US00/08821

the introduction to the wound site 12 of anti-microbial agents, whether alone or in combination with bFGF or other agents.

While the foregoing description is exemplary of the preferred embodiment of the present invention, those of ordinary skill in the relevant arts will recognize the many variations, alterations, modifications, substitutions and the like as are readily possible, especially in light of this description, the accompanying drawings and the claims drawn hereto. For example, those of ordinary skill in the art will recognize that while the preferred embodiment of the present invention comprises grafting the desired agent onto the foam pad 11 of the VAC system, those of ordinary skill in the art, with the benefit of this exemplary disclosure, will readily recognize many substantially equivalent modes for introduction of the

- disclosure, will readily recognize many substantially equivalent modes for introduction of the desired agent. For example, in the case of a foam pad 11 that has not been predisposed with an agent or that has been predisposed with an agent which, over time, has subsequently been exhausted into the wound site 12, the desired agent may be injected with a needle and syringe, or the like, through the wound drape 13 and into the foam pad 11. In any case,
- 15 because the scope of the present invention is much broader than any particular embodiment, the foregoing detailed description should not be construed as a limitation of the present invention, which is limited only by the claims appended hereto.

INDUSTRIAL APPLICABILITY:

20

The present invention is applicable to the wound healing arts.

PCT/US00/08821

CLAIMS:

What is claimed is:

A therapeutic combination for promoting wound healing in mammals, said
 therapeutic combination comprising:

a porous pad which is permeable to fluids and adapted for positioning within a sealable space defined in part by a wound surface;

a tube having a first end in fluid communication with said porous pad and a second end in fluid communication with a vacuum source, said vacuum source being adapted to 10 apply negative pressure to said porous pad through said tube; and

said porous pad being predisposed with a wound healing factor.

2. The therapeutic combination as recited in claim 1, wherein said wound healing factor comprises basic fibroblast growth factor.

15

3. The therapeutic combination as recited in claim 2, wherein said basic fibroblast growth factor is grafted to said porous pad.

4. The therapeutic combination as recited in claim 1, wherein said wound healing factor20 comprises an anti-microbial agent.

5. The therapeutic combination as recited in claim 4, wherein said anti-microbial agent comprises an antibiotic.

25 6. The therapeutic combination as recited in any of the preceding claims, wherein said porous pad is predisposed with a plurality of wound healing factors.


 The therapeutic combination as recited in any of the preceding claims, said therapeutic combination further comprising a wound drape for sealing said porous pad within
 said sealable space.

8. The therapeutic combination as recited in claim 7, wherein a quantity of a wound healing factor is introduced to said porous pad by injection through said wound drape.

WO 00/59424

9. The therapeutic combination as recited in claim 8, wherein said quantity of wound healing factor is in addition to said wound healing factor predisposed upon said porous pad.

10. The therapeutic combination as recited in claim 9, wherein said quantity of wound
5 healing factor comprises the same type of factor as said wound healing factor predisposed upon said porous pad.



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/08821

. CLASSIFICATION OF SUBJECT MATTER IPC(7) :AIF 13/00; A61M 1/00 A.

US CL :424/447-449; 604/36, 175, 305, 313, 316

According to International Patent Classification (IPC) or to both national classification and IPC

FIELDS SEARCHED B.

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/447-449; 604/36, 175, 305, 313, 316

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOC	UMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where app	propriate, of the relevant passages	Relevant to claim No.		
Х	US 5,466,465 A (ROYDS et al.) document.	14 November 1995, entire	1, 5-10		
X	US 5,358,494 A (SVEDMAN) 25 Octo	ober 1994, entire document.	1, 4-10		
Y	US 5,678,564 A (LAWRENCE et al document.	.) 21 October 1997, entire	1, 4-10		
Y	US 4,533,352 A (VAN BEEK et a document.	l.) 06 August 1985, entire	1, 4-10		
Y	US 4,525,166 A (LECLERC) 25 June	1985, entire document.	1, 4-10		
Eur	ther documents are listed in the continuation of Box C	See patent family annex.			
	pecial categories of cited documents:	"T" later document published after the in	ternational filing date or priority		
"A" c	ocument defining the general state of the art which is not considered	date and not in conflict with the appli principle or theory underlying the in	cation but cited to understand the		
"E" e	o be of particular relevance arlier document published on or after the international filing date locument which may throw doubts on priority claim(s) or which is	"X" document of particular relevance; t considered novel or cannot be consid when the document is taken alone	hered to involve an inventive step he claimed invention cannot be e step when the document is		
	ited to establish the publication date of another citation or other pecial reason (as specified)	"Y" document of particular relevance; t considered to involve an inventiv			
1	locument referring to an oral disclosure, use, exhibition or other means locument published prior to the international filing date but later than	combined with one or more other su being obvious to a person skilled in	ch documents, such combination the art		
	he promy date claimed	"&" document member of the same pater	nt family		
Date of the actual completion of the international search		Date of mailing of the international search report			
19 MAY	20 00	21 JUN 2000			
1		Yo '			
Commiss Box PCT	mailing address of the ISA/US noner of Patents and Trademarks on, D.C. 20231	Authorized officer			

Form PCT/ISA/210 (second sheet) (July 1998)*